CRC cell lines that were resistant to selumetinib exhibited low or no ERK1/2 activation or exhibited coincident activation of ERK1/2 and protein kinase B (PKB), the latter indicative of activation of the PI3K pathway. The gene discussed is MAPK3; the disease is colorectal carcinoma.